AI brief of an SEC Form 8-K · Strata Critical Medical, Inc. (SRTA)

Strata raises 2026 guidance; Q2 revenue up 60.7% to $72.5 million

Mixed Impact 4 of 5 earnings Written later

Strata reported second-quarter 2026 revenue of $72.5 million, up 60.7% from a year earlier, driven by acquisitions and organic Logistics growth. The net loss from continuing operations widened to $10.5 million, or $0.12 per share, from $3.4 million a year earlier, and included a $5.5 million non-cash charge for changes in fair value of assets and other liabilities. The company raised its 2026 revenue and Adjusted EBITDA guidance but left free cash flow guidance unchanged.

Key points

  • Q2 2026 Adjusted EBITDA was $7.9 million, up from $2.5 million in Q2 2025, with a 10.9% margin.
  • 2026 revenue guidance raised to $285-295 million from $260-275 million; Adjusted EBITDA guidance raised to $33-35 million from $29-33 million.
  • Free cash flow before aircraft and engine acquisitions guidance unchanged at $15-22 million.
  • Logistics gross margin fell to 18.4% in Q2 2026 from 20.0% a year earlier; cash and short-term investments were $22.8 million at June 30, 2026.

The filing

CompanyStrata Critical Medical, Inc. (SRTA)
Form8-K, current report
Filed with the SECAug 4, 2026, 7:13 AM ET
Accession number0001628280-26-052152

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.